Tokyo Tape
Sign in
← PHC Holdings

Half-year report · HY

6523.TEDINET S100X235
Period2025-04-01 → 2025-09-30
Filed2025-11-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥173.4bn2025-04-01 → 2025-09-30Cons.Revenue IFRS
Revenue¥361.6bn2024-04-01 → 2025-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥173.9bn2024-04-01 → 2024-09-30Cons.Revenue IFRS
Operating income¥10.4bn2025-04-01 → 2025-09-30Cons.Operating profit loss IFRS
Operating income¥9.2bn2024-04-01 → 2024-09-30Cons.Operating profit loss IFRS
Profit before tax¥941m2025-04-01 → 2025-09-30Cons.Profit loss before tax IFRS
Profit before tax¥18.8bn2024-04-01 → 2025-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥7.4bn2024-04-01 → 2024-09-30Cons.Profit loss before tax IFRS
Net income (owners)−¥559m2025-04-01 → 2025-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥10.5bn2024-04-01 → 2025-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥4.1bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income−¥692m2025-04-01 → 2025-09-30Cons.Profit loss IFRS
Net income¥4.0bn2024-04-01 → 2024-09-30Cons.Profit loss IFRS
Total assets¥525.8bnat 2025-09-30Cons.Assets IFRS
Total assets¥532.5bnat 2025-03-31Cons.Assets IFRS
Total assets¥525.4bnat 2024-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥379.8bnat 2025-09-30Cons.Liabilities IFRS
Total liabilities¥391.3bnat 2025-03-31Cons.Liabilities IFRS
Net assets / equity¥146.0bnat 2025-09-30Cons.Equity IFRS
Net assets / equity¥141.2bnat 2025-03-31Cons.Equity IFRS
Net assets / equity¥127.4bnat 2024-09-30Cons.Equity IFRS
Net assets / equity¥139.2bnat 2024-03-31vCons.Equity IFRS
Equity (owners)¥146.7bnat 2025-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥141.6bnat 2025-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥127.8bnat 2024-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥33.3bnat 2025-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥39.6bnat 2025-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥33.0bnat 2024-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥47.0bnat 2024-03-31vCons.Cash and cash equivalents IFRS
Operating cash flow¥12.1bn2025-04-01 → 2025-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥41.9bn2024-04-01 → 2025-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥13.8bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥4.2bn2025-04-01 → 2025-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥8.5bn2024-04-01 → 2025-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥5.0bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥17.6bn2025-04-01 → 2025-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥39.1bn2024-04-01 → 2025-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥20.9bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-4.422025-04-01 → 2025-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥83.132024-04-01 → 2025-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥32.522024-04-01 → 2024-09-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥-4.422025-04-01 → 2025-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥82.582024-04-01 → 2025-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥32.422024-04-01 → 2024-09-30Cons.Diluted earnings loss per share IFRS
Equity ratio27.9%at 2025-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio26.6%at 2025-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio24.3%at 2024-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2025-04-01 → 2025-09-30¥2.9bn
Reconciling Itemsreconcilingrevenue external2025-04-01 → 2025-09-30¥2.9bn
Reconciling Itemsreconcilingsegment profit2025-04-01 → 2025-09-30−¥3.2bn
Diabetes Managementreportable segmentrevenue2025-04-01 → 2025-09-30¥48.7bn
Diabetes Managementreportable segmentrevenue external2025-04-01 → 2025-09-30¥48.7bn
Diabetes Managementreportable segmentsegment profit2025-04-01 → 2025-09-30¥9.3bn
Diagnostics And Life Sciencesreportable segmentrevenue2025-04-01 → 2025-09-30¥59.1bn
Diagnostics And Life Sciencesreportable segmentrevenue external2025-04-01 → 2025-09-30¥59.1bn
Diagnostics And Life Sciencesreportable segmentsegment profit2025-04-01 → 2025-09-30¥1.3bn
Healthcare Solutionsreportable segmentrevenue2025-04-01 → 2025-09-30¥62.7bn
Healthcare Solutionsreportable segmentrevenue external2025-04-01 → 2025-09-30¥62.7bn
Healthcare Solutionsreportable segmentsegment profit2025-04-01 → 2025-09-30¥3.0bn
—segment totalrevenue2025-04-01 → 2025-09-30¥170.5bn
—segment totalrevenue external2025-04-01 → 2025-09-30¥170.5bn
—segment totalsegment profit2025-04-01 → 2025-09-30¥13.6bn
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30¥1.6bn
Reconciling Itemsreconcilingrevenue external2024-04-01 → 2024-09-30¥1.6bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥4.3bn
Diabetes Managementreportable segmentrevenue2024-04-01 → 2024-09-30¥48.3bn
Diabetes Managementreportable segmentrevenue external2024-04-01 → 2024-09-30¥48.3bn
Diabetes Managementreportable segmentsegment profit2024-04-01 → 2024-09-30¥6.4bn
Diagnostics And Life Sciencesreportable segmentrevenue2024-04-01 → 2024-09-30¥62.6bn
Diagnostics And Life Sciencesreportable segmentrevenue external2024-04-01 → 2024-09-30¥62.6bn
Diagnostics And Life Sciencesreportable segmentsegment profit2024-04-01 → 2024-09-30¥3.5bn
Healthcare Solutionsreportable segmentrevenue2024-04-01 → 2024-09-30¥61.5bn
Healthcare Solutionsreportable segmentrevenue external2024-04-01 → 2024-09-30¥61.5bn
Healthcare Solutionsreportable segmentsegment profit2024-04-01 → 2024-09-30¥3.6bn
—segment totalrevenue2024-04-01 → 2024-09-30¥172.3bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥172.3bn
—segment totalsegment profit2024-04-01 → 2024-09-30¥13.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 753
ItemContextValueUnit
Total transactions with owners IFRSInterimDuration_OtherComponentsOfEquityIFRSMember-211000000JPY
Total transactions with owners IFRSInterimDuration_EquityAttributableToOwnersOfParentIFRSMember-2366000000JPY
Total transactions with owners IFRSInterimDuration_NonControllingInterestsIFRSMember－JPY
Total transactions with owners IFRSInterimDuration-2366000000JPY
Equity IFRSInterimInstant_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember58983000000JPY
Equity IFRSInterimInstant_ShareOfOtherComprehensiveIncomeOfInvestmentsAccountedForUsingEquityMethodIFRSMember-26000000JPY
Equity IFRSInterimInstant_OtherComponentsOfEquityIFRSMember56286000000JPY
Equity IFRSInterimInstant_EquityAttributableToOwnersOfParentIFRSMember146658000000JPY
Equity IFRSInterimInstant_NonControllingInterestsIFRSMember-617000000JPY
Equity IFRSInterimInstant146041000000JPY
Profit loss before tax IFRSPrior1InterimDuration7411000000JPY
Profit loss before tax IFRSInterimDuration941000000JPY
Depreciation and amortization ope cf IFRSPrior1InterimDuration14310000000JPY
Depreciation and amortization ope cf IFRSInterimDuration13347000000JPY
Interest expenses ope cf IFRSPrior1InterimDuration3077000000JPY
Interest expenses ope cf IFRSInterimDuration2665000000JPY
Decrease increase in trade receivables ope cf IFRSPrior1InterimDuration8813000000JPY
Decrease increase in trade receivables ope cf IFRSInterimDuration6689000000JPY
Decrease increase in inventories ope cf IFRSPrior1InterimDuration-4023000000JPY
Decrease increase in inventories ope cf IFRSInterimDuration-4738000000JPY
Increase decrease in trade payables ope cf IFRSPrior1InterimDuration-4580000000JPY
Increase decrease in trade payables ope cf IFRSInterimDuration537000000JPY
Other changes in working capital ope cf IFRSPrior1InterimDuration-7705000000JPY
Other changes in working capital ope cf IFRSInterimDuration-658000000JPY
Subtotal ope cf IFRSPrior1InterimDuration17303000000JPY
Subtotal ope cf IFRSInterimDuration18784000000JPY
Interest and dividends received ope cf IFRSPrior1InterimDuration205000000JPY
Interest and dividends received ope cf IFRSInterimDuration97000000JPY
Interest paid ope cf IFRSPrior1InterimDuration-3381000000JPY
Interest paid ope cf IFRSInterimDuration-2622000000JPY
Income taxes paid ope cf IFRSPrior1InterimDuration-2454000000JPY
Income taxes paid ope cf IFRSInterimDuration-4235000000JPY
Income taxes refund ope cf IFRSPrior1InterimDuration2093000000JPY
Income taxes refund ope cf IFRSInterimDuration62000000JPY
Net cash provided by used in operating activities IFRSPrior1InterimDuration13767000000JPY
Net cash provided by used in operating activities IFRSInterimDuration12086000000JPY
Purchase of property plant and equipment and intangible assets inv cf IFRSPrior1InterimDuration-5897000000JPY
Purchase of property plant and equipment and intangible assets inv cf IFRSInterimDuration-4380000000JPY
Proceeds from sale of property plant and equipment and intangible assets inv cf IFRSPrior1InterimDuration206000000JPY
Proceeds from sale of property plant and equipment and intangible assets inv cf IFRSInterimDuration277000000JPY
Other inv cf IFRSPrior1InterimDuration707000000JPY
Other inv cf IFRSInterimDuration-139000000JPY
Net cash provided by used in investing activities IFRSPrior1InterimDuration-4983000000JPY
Net cash provided by used in investing activities IFRSInterimDuration-4242000000JPY
Net increase decrease in short term borrowings fin cf IFRSPrior1InterimDuration-1523000000JPY
Net increase decrease in short term borrowings fin cf IFRSInterimDuration-998000000JPY
Proceeds from long term borrowings fin cf IFRSPrior1InterimDuration－JPY
Proceeds from long term borrowings fin cf IFRSInterimDuration2999000000JPY
Repayments of long term borrowings fin cf IFRSPrior1InterimDuration-13518000000JPY
Repayments of long term borrowings fin cf IFRSInterimDuration-13937000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2025-03-31pass rounding
balance sheet identityconsolidated 2025-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2025-04-01/2025-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2025-04-01/2025-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2025-04-01/2025-09-30pass
statement vs summary · total assetsconsolidated 2025-03-31pass
statement vs summary · total assetsconsolidated 2025-09-30pass